Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nutex Health (NUTX) Receivables (2016 - 2026)

Nutex Health (NUTX) has disclosed Receivables for 17 consecutive years, with $6.3 million as the latest value for Q1 2026.

  • For Q1 2026, Receivables rose 46.51% year-over-year to $6.3 million; the TTM value through Mar 2026 reached $6.3 million, up 46.51%, while the annual FY2025 figure was $6.0 million, 39.53% up from the prior year.
  • Receivables hit $6.3 million in Q1 2026 for Nutex Health, up from $6.0 million in the prior quarter.
  • Across five years, Receivables topped out at $95.9 million in Q2 2022 and bottomed at $793946.0 in Q1 2022.
  • Average Receivables over 5 years is $27.9 million, with a median of $6.3 million recorded in 2026.
  • Year-over-year, Receivables skyrocketed 28525.17% in 2022 and then tumbled 93.23% in 2024.
  • Nutex Health's Receivables stood at $58.3 million in 2022, then grew by 0.45% to $58.6 million in 2023, then tumbled by 92.66% to $4.3 million in 2024, then soared by 39.53% to $6.0 million in 2025, then rose by 5.0% to $6.3 million in 2026.
  • According to Business Quant data, Receivables over the past three periods came in at $6.3 million, $6.0 million, and $7.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.